Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PaedsSeq

Financiado

Cerrado

Nanopore sequencing of cell free DNA for the sensitive detection molecular prof...

Nanopore sequencing of cell free DNA for the sensitive detection molecular profiling and monitoring of childhood cancers Paediatric cancer is the leading cause of death in children post infancy in the Western world. The integration of high-throughput molecular profiling is now urgently needed to guide clinical decision-making and treatment stratific... ver más

31/05/2025

EMBL

221K€

Presupuesto del proyecto: 221K€

Líder del proyecto

EUROPEAN MOLECULAR BIOLOGY LABORATORY No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-03

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

EMBL

220.91K€ | Lider

UoB

N.D. | Participante

Proyectos interesantes

CANCEREVO

Medical Technol...

Data Science

2M€ Cerrado

EQC2018-004733-P

Medical Technol...

Data Science

171K€ Cerrado

ONCOTRACK

Medical Technol...

Data Science

31M€ Cerrado

ONCOTECT

Medical Technol...

Data Science

71K€ Cerrado

SAF2015-64157-R

Medical Technol...

Data Science

182K€ Cerrado

EpiDetect

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 25 meses Fecha Inicio: 2023-04-03
Fecha Fin: 2025-05-31

Líder del proyecto

EUROPEAN MOLECULAR BIOLOGY LABORATORY No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 221K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Paediatric cancer is the leading cause of death in children post infancy in the Western world. The integration of high-throughput molecular profiling is now urgently needed to guide clinical decision-making and treatment stratification. However, access to adequate tumour material for genomic profiling remains highly challenging, particularly in children with refractory cancers, due to sampling difficulties and small sample volumes. The analysis of cell-free DNA (cfDNA) from liquid biopsies for the detection of circulating tumour DNA (ctDNA) could offer a powerful, minimally invasive alternative to tumour profiling, thus circumventing sampling limitations. However, current ctDNA approaches have limited specificity and sensitivity, and their clinical implementation is hindered by poor scalability and high costs associated with conventional sequencing technologies. In contrast, emerging nanopore sequencing platforms have faster turnaround times, are more affordable and significantly smaller than conventional sequencers, making them easy to deploy and implement in healthcare settings. However, their utility for cfDNA analyses remains largely unexplored. Here, using available data and liquid biopsy samples from ~500 children with cancer, I will develop computational tools for the detailed analysis of cfDNA nanopore sequencing data. By harnessing nanopore’s ability to sequence native DNA, thus allowing the detection of mutational DNA alterations and epigenetic modifications from the same assay, I will: (a) establish highly sensitive and specific approaches for the detection and molecular profiling of ctDNA, (b) develop methylation-based disease classifiers for accurate diagnosis and treatment stratification, and (c) evaluate the clinical utility of cfDNA nanopore sequencing to monitor treatment response and detect cancer relapse. The clinical implementation of these approaches could therefore significantly improve disease management and outcomes for children with cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores